Cargando…
Effects of EpCAM overexpression on human breast cancer cell lines
BACKGROUND: Recently, EpCAM has attracted major interest as a target for antibody- and vaccine-based cancer immunotherapies. In breast cancer, the EpCAM antigen is overexpressed in 30-40% of all cases and this increased expression correlates with poor prognosis. The use of EpCAM-specific monoclonal...
Autores principales: | Gostner, Johanna M, Fong, Dominic, Wrulich, Oliver A, Lehne, Florian, Zitt, Marion, Hermann, Martin, Krobitsch, Sylvia, Martowicz, Agnieszka, Gastl, Guenther, Spizzo, Gilbert |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3042418/ https://www.ncbi.nlm.nih.gov/pubmed/21281469 http://dx.doi.org/10.1186/1471-2407-11-45 |
Ejemplares similares
-
Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas
por: Fong, Dominic, et al.
Publicado: (2014) -
Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines
por: Martowicz, Agnieszka, et al.
Publicado: (2012) -
EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth
por: Martowicz, Agnieszka, et al.
Publicado: (2013) -
Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro
por: Seeber, Andreas, et al.
Publicado: (2015) -
EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis
por: Spizzo, Gilbert, et al.
Publicado: (2011)